Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Perhaps Cliff Holloway set it up to support an upcoming job interview š
Why wasnāt what RNSād?
"ā¦..many corporate mergers fail due to having too many executives for the post-merger number of executive chairs available. I donāt think that will be a problem with Scancellā¦ā¦"
So this sounds like a good thing i.e. a streamlined organisation? But why wasn't this RNS'd?
I've lost track how many conferences and more importantly how many presentations there have been this year already. Seems very different from previous years IMO.
"Donāt think it is Scancell". Yes, looking at the choice of videos as Bermuda mentions, doesn't look official. Odd that someone has taken it upon themselves to do that?
Must be Lofas then
Donāt think it is Scancell
WTP
Not sure whether it was even set up by Scancell. In a way I hope it wasn't because it's a strange selection of videos to start the channel with. A 3 year old video to mark their move to the Oxford Science Park which is essentially all about the building and facilities and another from 2017 with a long since departed CEO. Not sure either reflect the Scancel we see today.
As posted on a BB for a different company:
https://www.thisismoney.co.uk/money/comment/article-13341575/Dont-let-Nasdaq-aim-AIM-market-says-MAGGIE-PAGANO.html
Rumours are that Nasdaq are interested in buying the AIM market from the London Stock Exchange group.
If such a deal were to go though, it would surely be a good thing for companies such as Scancell.
Wonder what's prompted that after all these years of not having a YouTube channel.
Scancell has a youtube channel with 2 videos uploaded yesterday
https://www.youtube.com/@Scancell-ltd
Anyone interested in the application of AI to vaccine development may want to put Bloomberg TV on right now. Just about to discuss application and dramatic time-shortening in researchā¦..
Yes really quick because it's actually 10 minutes plus 5 minutes for questions ! Am sure it's more than enough to get across the headline figures though and good that Scancell have had an abstract selected for oral presentation.
Thanks Bermuda - Dr Peston will just have to talk quickly then!
Rats,
Think the slot for the presentation is 15 minutes. Apparently all abstracts will be published on the conference website on Monday (13th May) so hopefully we should be able to access them.
Rat, you are correct...17th of May is a Friday ...not a Thursday as stated in the RNS.....if Scancell was responsible for the error then its sloppy housekeeping . Perhaps this is why we have no deals...team Scancell turn up on the wrong date and find the room empty š¤£š¤£
Rats it would appear from the program its Friday 17th from 10.45 - 11.00
Good to see the presentation is a 90 minute slot - maybe some more results to come ahead of it perhaps?
Does the RNS mean Thursday 16th or is it on Friday 17th?
Iām also a tad confused and wonder if someone could help me out please.
Does any part of the RNS link in with the silencing technology from Oxford-based mAbsolve, or is that a completely different thread from the past?
Hi Burble,
Where is the reference to Modi-1 patients in connection with the isolation please?
Oral presentation sounds interesting, but even more exciting will be the two posters.
- development of CAR-T from the GlymAbs
- isolation of TCR from Modi-1 patients
Is this new?
by functional T cell responses to the TRP2 and gp100 peptides which can be detected in patients post vaccination
Not really relevant, given market caps and failing companiesā¦..
British biotech start-up backed by Snoop Dogg has unveiled plans to ditch the āturbulentā London stock market, dealing a fresh blow to the beleaguered exchange.
Oxford Cannabinoid Technologies said it was delisting from London following a ācontinuous, irrational and regressive pressureā on its share price. The company claimed it would be much better valued as a private company and would also not have to bear the āsubstantial costā of maintaining a public listing.
Clarissa Sowemimo-Coker, chief executive of Oxford Cannabinoid Technologies, said: āIt has been a turbulent time on the capital markets pretty much since we listed. The last 12 to 24 months have been especially challenging for small caps and particularly in the biopharma space. Companies have lost 80pc or 90pc of their value and once youāre down there, itās very difficult to make any inroads to start climbing back up again.ā
She said this was having knock-on effects when it came to bringing new treatments to market: āThings do take longer when youāre trying to stretch for capital. You inevitably slow down drug development.ā
Ms Sowmimo added: āWe anticipate that as an unlisted company, a far larger pool of capital may be available to us, and therefore it is right for us to make this change.ā
The British biotech, which landed a $10m (Ā£8m) cash injection from Snoop Dogg five years ago, joined the London Stock Exchange in 2021. Since then, it has lost 97pc of its value. The company said it expected to go public again āin due courseā but that it was more likely that this would be in the US.
Ms Sowmimo-Coker said: āWeāre intending to go away for a few years and weād hope that the London markets will have undergone a rejuvenation by then. But also Nasdaq is an opportunity and lots of others are going there.ā
Ms Sowminmo-Coker said there was a āfair bit of red tapeā in the market and also called for more to be done on bolstering institutional investment into companies following years of dwindling support.
The announcement will add to growing concerns over the future of the London market, which has been battling a wave of company exits in recent months. Biotechnology companies, in particular, have been vocal in their criticism of Londonās public markets, which bosses have claimed is preventing early-stage research businesses from being able to spend on new treatments.
Last month, Redx Pharma said it was quitting the Alternative Investment Market (AIM), claiming its low valuation was ānot conduciveā to raising cash to spend on more treatments.
C4X Discovery also unveiled plans to leave AIM earlier this year, saying the recent downturn in the financial markets āadversely impacted our share price, and with it, our future ability to raise funds in the public marketsā.
It prompted a warning from Sir John Bell, one of Britainās top life sciences leaders, that more drug makers could follow. He branded the City